Targeting sphingosine kinase 2 (SphK2) has become a novel strategy for the treatment of cancer. However, potent and selective SphK2 inhibitors are rare. In our work, a series of novel SphK2 inhibitors were innovatively designed, synthesized and screened. Compound 12e showed the best inhibitory activity. Molecular dynamics simulations were carried out to analyze the detailed interactions between the SphK2 and its inhibitors. Moreover, 12e exhibited anti-proliferative activity in various cancer cells, and inhibited the migration of human breast cancer cells MCF-7.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2023.117441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
S1P/S1PRs-TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis.
Br J Pharmacol
November 2024
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing, China.
Article Synopsis
- * Researchers analyzed lesional skin in CD model mice using advanced techniques, revealing a significant increase in sphingosine-1-phosphate (S1P) and identifying 136 altered compounds mainly linked to sphingolipid metabolism.
- * The study found that S1P promotes chronic pain and itch through the TRPV4 channel, suggesting that targeting S1P synthesis or its pathways could lead to effective treatments for CD symptoms.
Syntheses of differentially fluorinated triazole-based 1-deoxysphingosine analogues to SphK inhibitors.
Org Biomol Chem
November 2024
Universitat Rovira i Virgili, Departament de Química Analítica i Química Orgànica, Faculty of Chemistry, C/Marcel·lí Domingo 1, 43007 Tarragona, Spain.
This study focuses on the stereoselective syntheses of 1-deoxysphingosine analogues as potential inhibitors of sphingosine kinase (SphK), particularly targeting its isoforms SphK1 and SphK2, which are implicated in cancer progression and therapy resistance. The research builds on previous work by designing a series of analogues featuring systematic structural modifications like the incorporation of a triazole ring, varying degrees of fluorination, and different head groups (, guanidino, -methylamino, and ,-dimethylamino). These modifications aimed to enhance polar and hydrophobic interactions especially with SphK2.
View Article and Find Full Text PDFSPHK2 Knockdown Inhibits the Proliferation and Migration of Fibroblast-Like Synoviocytes Through the IL-17 Signaling Pathway in Osteoarthritis.
J Inflamm Res
October 2024
Department of Sports Medicine, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou City, Hainan Province, 570311, People's Republic of China.
Objective: Synovial inflammation is vital for the progression of osteoarthritis (OA). The objective of this study was to explore the effects and potential molecular mechanisms of sphingosine kinase 2 (SPHK2) on the proliferation and migration of fibroblast-like synoviocytes (FLS).
Methods: A TNF-α-stimulated FLS model and a papain-induced OA rat model were constructed.
A role for plasma membrane Ca ATPases in regulation of cellular Ca homeostasis by sphingosine kinase-1.
Pflugers Arch
December 2024
Institut Für Allgemeine Pharmakologie Und Toxikologie, Goethe-Universität Frankfurt, Universitätsklinikum, Frankfurt am Main, Germany.
Sphingosine-1-phosphate (S1P) is a ubiquitous lipid mediator, acting via specific G-protein-coupled receptors (GPCR) and intracellularly. Previous work has shown that deletion of S1P lyase caused a chronic elevation of cytosolic [Ca] and enhanced Ca storage in mouse embryonic fibroblasts. Here, we studied the role of sphingosine kinase (SphK)-1 in Ca signaling, using two independently generated EA.
View Article and Find Full Text PDFTargeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition.
World J Oncol
October 2024
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Background: Epithelial-to-mesenchymal transition (EMT), cancer stem cells (CSCs), and colorectal cancer (CRC) therapy resistance are closely associated. Prior reports have demonstrated that sphingosine-1-phosphate (S1P) supports stem cells and maintains the CSC phenotype. We hypothesized that the EMT inducer SNAI1 drives S1P signaling to amplify CSC self-renewal capacity and chemoresistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!